7.06 Cell Biology QUIZ #4

Similar documents
What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

Cancer: DNA Synthesis, Mitosis, and Meiosis

Fulfilling the Promise

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Update in Hematology Oncology Targeted Therapies. Mark Holguin

A disease of populations of cells that live, divide, invade and spread without regard to normal limits

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

Acute Myeloid Leukemia

The Treatment of Leukemia

Acute myeloid leukemia (AML)

7.012 Quiz 3 practice

Stem Cells: The Real Culprits in Cancer?

ACUTE MYELOID LEUKEMIA (AML),

How To Expand Hematopoietic Stem Cells

Types of Cancers [-oma growth ]!

March 19, Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

Mutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base

What is a Stem Cell Transplantation?

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

An Overview of Cells and Cell Research

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

CANCER TREATMENT: Chemotherapy

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

Cytotoxic and Biotherapies Credentialing Programme Module 2

Answering your questions on Chronic Myeloid Leukaemia (CML)

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More

Cytogenetics for the Rest of Us: A Primer

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

Unit 1 Higher Human Biology Summary Notes

Microarray Technology

CHAPTER 2: UNDERSTANDING CANCER

A disease and antibody biology approach to antibody drug discovery

A Genetic Analysis of Rheumatoid Arthritis

Stem Cell Quick Guide: Stem Cell Basics

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes

Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi

Chapter 18: Applications of Immunology

DNA Microarrays (Gene Chips) and Cancer

Cell Biology Questions and Learning Objectives

Other treatments for chronic myeloid leukaemia

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Course Curriculum for Master Degree in Medical Laboratory Sciences/Hematology and Blood Banking

How Cancer Begins???????? Chithra Manikandan Nov 2009

The Human Genome Project. From genome to health From human genome to other genomes and to gene function Structural Genomics initiative

Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

Cancer can occur at almost any organ in the body

If you were diagnosed with cancer today, what would your chances of survival be?

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

KMS-Specialist & Customized Biosimilar Service

PART 3.3: MicroRNA and Cancer

Biochemistry of Cancer Cell

Blood-Forming Stem Cell Transplants

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation

My Sister s s Keeper. Science Background Talk

The Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire

Targeted Therapies in Lung Cancer

The CML Guide Information for Patients and Caregivers

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs)

Leukemia Research Foundation Scientific Research Grant Recipients

Exercise 9: Blood. Readings: Silverthorn 5 th ed, , ; 6 th ed, ,

Blood-Based Cancer Diagnostics

CCR Biology - Chapter 9 Practice Test - Summer 2012

How to construct transgenic mice

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

How to construct transgenic mice

Microbiology AN INTRODUCTION EIGHTH EDITION

Stem Cell Transplantation

DNA Fingerprinting. Unless they are identical twins, individuals have unique DNA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights

On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

GRANIX (tbo-filgrastim)

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Can receive blood from: * I A I A and I A i o Type A Yes No A or AB A or O I B I B and I B i o Type B No Yes B or AB B or O

RADIATION THERAPY FOR LYMPHOMA. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

Trasposable elements: P elements

Developments in Biomarker Identification and Validation for Lung Cancer

Head of College Scholars List Scheme. Summer Studentship. Report Form


The Immune System: A Tutorial

Lecture 13: DNA Technology. DNA Sequencing. DNA Sequencing Genetic Markers - RFLPs polymerase chain reaction (PCR) products of biotechnology

Our body is a community of

Corporate Medical Policy

Muscular Dystrophy: Stem Cell Therapy

Transcription:

TA Name and Recitation Time: 7.06 Cell Biology QUIZ #4 This is an open book exam, and you are allowed access to books and notes, but not computers or any other types of electronic devices. Please write your answers to questions in pen (not pencil) in the space allotted. Please write only on the FRONT SIDE of each sheet. And be sure to put your name on each page in case they become separated. There are 10 pages to the quiz, make sure you have a complete copy! Remember that we will Xerox all of the quizzes. Good Luck! Question 1. Question 2. Question 3. Question 4. 25 pts 20 pts 30 pts 25 pts 1

Question 1. (25 points) You are interested in studying actin dynamics. Your advisor gives you purified G actin- ATP monomers and two proteins she is convinced affect actin dynamics. She also provides you with the Myosin S1 protein fragment. 1a. (2 points) Draw the profile you observe when you add an actin nucleator seed of polymerized actin to a G-actin-ATP solution at a concentration above the critical concentration (Cc) for the - end. Assume the time course goes long enough that equilibrium is reached. Filament mass time 1b. (5 points) Draw the profile you observe when you add actin nucleator seed of polymerized actin to a G-actin-ATP solution at a concentration between the Cc for the + end and the Cc for the end. Filament mass time What is the term for what is observed? 2

1c. (9 points) When you add Protein X to a reaction with an actin nucleator seed of polymerized actin and G-actin-ATP at a concentration above the critical concentration (Cc) for the end you observe the following: Addition of Protein X Filament mass time Propose two possible functions for Protein X and design an experiment to distinguish these functions. 1d. (3 points) When you add Protein Y you do not observe an effect on filament mass. You show by co-immunoprecipitation that Protein Y will bind to actin microfilaments but not to monomers. When you attach Protein Y to a microscope slide and then add fluorescently labeled microfilaments you observe they glide across the microscope slide. Explain this observation and the function of Protein Y. 3

1e. (6 points) You coat microfilaments with the myosin S1 fragment and add these coated microfilaments to the slide with Protein Y stuck on a slide. You observe the coated microfilaments move, and they move in the direction with the barbed ends leading. Protein Y Microfilament movement Your advisor is ecstatic with this observation, telling you that you have made a major discovery. What is novel about this discovery? Question 2. (20 points) You recover a mouse mutant in which the skin is severely blistered. The mutation maps near the gene encoding the alpha6 integrin protein. 2a. (5 points) You make a cell line from the skin epithelial cells of this mutant mouse. What are two methods you could use with these cells to test whether the mutant phenotype could be the consequence of mutation of this integrin gene? Explain the predicted results for each approach. 4

2b. (5 points) Why would a mutation in integrin cause blistering of the skin? What other proteins would you expect to produce this phenotype when mutated and why? 2c. (5 points) In a wild-type mouse if you irradiate the skin with UV light to produce melanoma skin cancer it is rare for it to metastasize to the lung, but after irradiation of the blistered mutants with UV light the mice readily develop lung cancer from the melanomas. Explain this observation. 2d. (5 points) You have a different mouse that has an autoimmune disorder with antibodies against the RGD peptide. Would you expect it to be more or less susceptible to metastasis than wild type and why? Question 3. (30 points) You are an oncologist asked to treat two patients with early stage prostate cancer. You decide to evaluate the status of candidate oncogenes and tumor suppressor genes and make interesting observations when testing Cyclin D. 3a. (10 points) Genomic DNA is isolated from blood or prostate. A Southern blot of genomic DNA cut with a restriction enzyme that cuts rarely and hybridized with a probe for Cyclin D shows the following result: 5

Unaffected male Patient #1 Patient #2 Blood Prostate Blood Prostate Blood Name: Prostate Direction of migration A Western blot shows the following: Unaffected male Patient #1 Patient #2 Blood prostate Blood Prostate Blood Prostate Propose a molecular explanation for the change in the cyclin D gene in each of the patients, explaining how each could account for the prostate cancer. Explain how your model accounts for the Western result. 6

3b. (3 points) Your patients ask whether their sons are likely to be predisposed to prostate cancer. For each patient do you answer yes or no, and why? 3c. (8 points) During the course of a year following these patients, the tumor in patient #1 suddenly becomes much larger. You test the p53 gene and protein in this patient by Southern and Western blots. Unaffected male Patient #1 Unaffected male Patient #1 Blood Prostate Blood Prostate Blood Prostate Blood Prostate Southern blot Western blot What type of mutation is consistent with the above data? Propose two reasons why such a change is correlated with the large size of the tumor. 7

3d. (3 points) Do you think it would be good to treat patient #1 with a drug that blocks blood vessel formation by angiogenesis? Why or why not? 3e. (3 points). One of your colleagues has identified a chemical that causes extensive DNA damage that leads to death of proliferating cells. Would this be helpful as a chemotherapy agent for patient #1? If yes, explain why. If no, explain what properties of a chemotherapy agent are needed. 3f. (3 points) Your colleague also has a chemical that will induce apoptosis even in cells lacking p53 and that can be specifically delivered to tumors. Would this be a positive therapy for patient #1? Why or why not? Question 4. (25 points) Recent research suggests that some cancers may be caused by unregulated division within populations of stem cells. There is evidence for breast cancer, lung cancer, and leukemia stem cells. You decide to use a mouse model to test whether leukemia is caused by transformed stem cells in the hematopoietic lineage. 4a. (2 points) You have a mouse strain with the bcr-abl translocation that has chronic Chronic myelogenous leukemia (CML). Occasionally one of these mice develops a more severe acute CML. What is the likely explanation for the change from chronic to acute CML? 4b. (4 points) You take a mouse with acute CML, irradiate it to eliminate the bone marrow cells, and inject bone marrow from a wild-type mouse. The irradiated mouse recovers and no longer shows signs of leukemia. Explain why the mouse recovered 8

with the donor bone marrow and why its leukemia is in remission. Does this experiment show that the leukemia is caused by stem cells? 4c. (8 points) You isolate myeloid and lymphoid stem cells using antibodies to known cell surface markers and FACS to purify cells. You grow the lymphoid stem cells in culture media that causes them to maintain a pattern of asymmetric divisions. You plate 200 lymphoid stem cells. After four division cycles, how many lymphoid stem cells do you have? How many T cell or B CFC cell progenitors do you have? (assume they divide at the same rate as the stem cells) 4d. (7 points) You make your bcr-abl mutant mouse transgenic such that GFP is expressed in each of its cells under the alpha-tubulin promoter. You purify lymphoid 9

stem cells from this mutant mouse and myeloid stem cells from an unlabeled, wild-type mouse. When you inject these two populations of stem cells into an irradiated wild-type mouse you observe that it gets leukemia, and the transformed B cells express GFP. Explain your conclusions from this experiment. 4e. (4 points) Your oncologist friend who is treating a patient with human CML wants to give the patient high doses of irradiation and then a bone marrow transplant. To avoid immune rejection he has decided to collect the patient s own bone marrow prior to irradiation and then use this for the transplant after irradiation. Based on your experiments what advice do you give him about his proposed therapy and what is your reasoning? 10